

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**May 10, 2018  
(Date of earliest event reported)**

---

**LABORATORY CORPORATION OF AMERICA  
HOLDINGS**

**(Exact Name of Registrant as Specified in its Charter)**

---

**DELAWARE**  
(State or other jurisdiction  
of Incorporation)

**1-11353**  
(Commission  
File Number)

**13-3757370**  
(I.R.S. Employer  
Identification No.)

**358 SOUTH MAIN STREET,  
BURLINGTON, NORTH CAROLINA**  
(Address of principal executive offices)

**27215**  
(Zip Code)

**336-229-1127**  
(Registrant's telephone number including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The 2018 Annual Meeting of Shareholders (the “Annual Meeting”) of Laboratory Corporation of America Holdings (the “Company”) was held on May 10, 2018. As of March 23, 2018, the date of record for determining the Company’s shareholders entitled to vote on the proposals presented at the Annual Meeting, there were 102,001,292 shares of the Company’s common stock issued and outstanding and entitled to vote at the Annual Meeting. The holders of 88,654,359 shares of the Company’s issued and outstanding common stock were represented in person or by proxy at the Annual Meeting, constituting a quorum. The proposals presented at the Annual Meeting are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 30, 2018. The vote results detailed below represent final results as certified by the Inspector of Elections.

**Proposal 1.**

The Company’s shareholders elected the following persons, who were listed in the Proxy Statement, to the Company’s Board of Directors to hold office for the term expiring at the 2019 Annual Meeting of Shareholders or until their successors are elected and qualified or until their earlier death, resignation or removal:

	<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
David P. King	75,801,416	4,766,131	116,258	7,970,554
Kerri B. Anderson	78,634,054	1,976,408	73,343	7,970,554
Jean-Luc Bélingard	64,768,266	15,841,113	74,426	7,970,554
D. Gary Gilliland, M.D., Ph.D.	79,773,937	836,615	73,253	7,970,554
Garheng Kong, M.D., Ph.D.	63,067,256	17,543,682	72,867	7,970,554
Robert E. Mittelstaedt, Jr.	78,173,193	2,437,111	73,501	7,970,554
Peter M. Neupert	78,545,568	2,000,446	137,791	7,970,554
Richelle P. Parham	79,349,007	1,262,792	72,006	7,970,554
Adam H. Schechter	80,341,618	269,347	72,840	7,970,554
R. Sanders Williams, M.D.	79,027,862	1,584,070	71,873	7,970,554

**Proposal 2.**

The Company’s shareholders approved, in an advisory (non-binding) vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
76,820,514	3,635,677	227,614	7,970,554

**Proposal 3.**

The Company’s shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. The votes regarding this proposal were as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
85,188,310	3,377,250	88,799	0

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Registrant

By: /s/ Sandra van der Vaart

\_\_\_\_\_  
Sandra van der Vaart

Senior Vice President and Deputy Chief Legal Officer

Dated: May 31, 2018